European Lung Cancer Conference (ELCC 2017)

Präsenzveranstaltung

The conference is relevant for medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians, and other medical professionals involved in the diagnosis, treatment and follow-up of patients with lung cancer.

Lung cancer killed approximately 1,590,000 persons in 2012 and is currently the leading cause of cancer death worldwide (1). Tobacco use is a major risk factor for lung cancer and is responsible for approximately 22% of cancer-related deaths globally. Lung cancer is the leading cause of cancer deaths in males and the second leading cause in females globally. In 2012, lung cancer killed an estimated 1,098,700 men and 491,200 women worldwide, corresponding to 24% and 14% of all cancer deaths in males and females, respectively. In developed countries, it is now the leading cause of cancer death in females, surpassing breast cancer.

The European Lung Cancer Conference is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

Issues:

• Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC?
• Keynote lecture: Molecular clonal development of lung cancer
• Malignant pleural mesothelioma
• Optimal management of stage III NSCLC in 2017
• Rare thoracic malignancies
• The role of the pathologist in guiding therapy
• ESMO recommendations (NSCLC, SCLC, Meothelioma, Thymic)